Business
Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field
About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update. Highlights for Recent Weeks: Phase 1b data for JSP191 in the treatment of patients with MDS or AML accepted for presentation as a late breaking oral abstract at the Tandem Meetings of ASTCT and CIBMTR on April 26th, 2022. Data from 17 patients show JSP191, in combination with low dose radiation and fludarabine conditioning, was well tolerated in patients 62 to 79 years old with no JSP191-related serious adverse events. Primary engraftment with neutrophil recovery was achieved in all 17 subjects and clearance of MRD was observed in 12 of the 15 subjects positive for MRD at screening Initiation of a new study of JSP191 as a second-line therapeutic for patients with lower risk MDS expected to start in 2022 Data showing long-term benefits of HSC engraftment following single-agent JSP191 conditioning in patients with SCID to be presented at the Clinical Immunology Society annual meeting (March 31-April 2) Continued pipeline progress, including JSP191 across multiple gene therapy collaborations and Jasper’s mRNA stem cell graft platform Appointment of Ronald Martell as Chief Executive Officer and President “During 2021, our team made significant strides advancing JSP191, our anti-CD117 monoclonal antibody, and demonstrating its potential to transform the treatment of multiple diseases by providing a safer and more effective stem-cell transplant therapy,” said Ronald Martell, Chief Executive Officer of Jasper Therapeutics. “Recently we’ve seen the presentation of compelling data pointing to the potential of this asset as a conditioning agent in severe combined immunodeficiency (SCID), with results showing JSP191 to be well tolerated with no treatment-related adverse events in patients ranging from 3 months to 38 years. Next month, we look forward to the presentation of updated results from our Phase 1b study of JSP191 in the treatment of myelodysplastic syndromes and acute myeloid leukemia (MDS/AML) at the ASTCT/CIBMTR meetings. Initial data from this study also showed JSP191 to be well-tolerated and achieved 100% successful engraftment with cle...